PE20091067A1 - Variantes de peptidos natriureticos de tipo c - Google Patents

Variantes de peptidos natriureticos de tipo c

Info

Publication number
PE20091067A1
PE20091067A1 PE2008001957A PE2008001957A PE20091067A1 PE 20091067 A1 PE20091067 A1 PE 20091067A1 PE 2008001957 A PE2008001957 A PE 2008001957A PE 2008001957 A PE2008001957 A PE 2008001957A PE 20091067 A1 PE20091067 A1 PE 20091067A1
Authority
PE
Peru
Prior art keywords
gly
peptide
isosters
asn
leu
Prior art date
Application number
PE2008001957A
Other languages
English (en)
Inventor
Dan J Wendt
Mika Aoyagi-Scharber
Sean M Bell
Dong Wei
Joshua R Bliesath
Emil D Kakkis
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091067(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20091067A1 publication Critical patent/PE20091067A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA VARIANTE DEL PEPTIDO NATRIURETICO DE TIPO C (CNP) DE FORMULA: (X)-Gly1-Leu2-Ser3-(a)4-Gly5-(b)6-(c)7-(d)8-(e)9-(f)10-(g)11-Asp12-Arg13-(h)14-(i)15-Ser16-(j)17-Ser18-Gly19-(k)20-Cys22-(Z) (SEQ ID N:50), DONDE: (X) E (Z) PUEDEN ESTAR AUSENTES O SON GRUPOS DE DIRECCIONAMIENTO A HUESOS O CARTILAGO, GRUPOS QUE REDUCEN LA DEPURACION RENAL, POLIMEROS HIDROFILICOS, SECUENCIAS DE AMINOACIDOS QUE COMPRENDEN UNO O MAS AMINOACIDOS, CARBOHIDRATOS, ACIDOS HIDROFOBICOS Y COMBINACIONES DE LOS MISMOS; (a) Y (f) SON CADA UNO Lys DE TIPO SALVAJE, AMINOACIDO NATURAL, AMINOACIDO NO NATRUAL, PEPTIDOMIMETICO QUE NO TIENE UN GRUPO PRIMARIO REACTIVO SOBRE UNA CADENA LATERAL, (b) ES Cys, ISOSTEROS DE ENLACES PEPTIDICOS; (c) L-Phe; D-Phe, ACIDO 3-AMINO-2-FENILPROPIONICO, DERIVADOS N-ALQUILADOS, ENTRE OTROS; (d) ES Gly, TER-BUTIL-Gly, Thr, Ser, ENTRE OTROS; (e) ES Leu, Ser, Thr, ISOSTEROS DE ENLACES PEPTIDICOS; (g) ES Leu, Asn, ISOSTEROS DE ENLACES PETIDICOS; (h) ES Ile, TER-BUTIL-Gly, Asn, ISOSTEROS DE ENLACES PEPTIDICOS; (i) ES Gly, Arg, Ser, Asn; (k) ES Leu,NORLEUCINA, Val, ENTRE OTROS. DICHA VARIANTE CNP ES UTIL EN EL TRATAMIENTO DE ACONDROPLASIA, ENANISMO, DISPLASIA TANATOFORICA, ENTRE OTROS
PE2008001957A 2007-11-21 2008-11-24 Variantes de peptidos natriureticos de tipo c PE20091067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98949707P 2007-11-21 2007-11-21
US6148808P 2008-06-13 2008-06-13

Publications (1)

Publication Number Publication Date
PE20091067A1 true PE20091067A1 (es) 2009-08-12

Family

ID=40364250

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001957A PE20091067A1 (es) 2007-11-21 2008-11-24 Variantes de peptidos natriureticos de tipo c

Country Status (10)

Country Link
US (1) US8377884B2 (es)
EP (1) EP2217620A2 (es)
JP (1) JP2011504506A (es)
AR (1) AR069409A1 (es)
AU (1) AU2008326327A1 (es)
CA (1) CA2705603A1 (es)
CL (1) CL2008003476A1 (es)
PE (1) PE20091067A1 (es)
TW (1) TWI367213B (es)
WO (1) WO2009067639A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
PT2432489T (pt) * 2009-05-20 2016-12-07 Biomarin Pharm Inc Variantes do péptido natriurético de tipo c
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
US20120208756A1 (en) 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
WO2011024973A1 (ja) 2009-08-27 2011-03-03 株式会社 イギス 鼻炎治療剤
WO2011038061A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
WO2011075471A2 (en) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
US20110300071A1 (en) * 2010-06-04 2011-12-08 Washington University Targeting npr-c in angiogenesis and atherosclerosis with a c-type atrial natriuretic factor (canf)-comb nanocomplex
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
MX353295B (es) 2011-01-21 2018-01-08 Endo Kyoko Agente para el tratamiento de la alopecia.
WO2012118042A1 (ja) 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
WO2013027680A1 (ja) 2011-08-19 2013-02-28 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体gc-aアゴニスト及びgc-bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
KR20140084201A (ko) * 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
WO2013095759A1 (en) * 2011-12-23 2013-06-27 Mayo Foundation For Medical Education And Research Assessing renal structural alterations and outcomes
EP2853273A4 (en) * 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd PROMOTER FOR BONE REPAIR
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CA2882881A1 (en) 2013-03-10 2014-09-18 National University Corporation Nagoya University Therapeutic agent for systemic bone disease and use thereof
KR20160118264A (ko) * 2014-02-27 2016-10-11 다이이찌 산쿄 가부시키가이샤 스테로이드제 투여로 유발되는 성장 장해에 대한 의약
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
EP3242689A1 (en) * 2015-01-09 2017-11-15 Ascendis Pharma Growth Disorders A/S Cnp prodrugs
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
DK3328416T5 (da) 2015-07-30 2024-10-07 Biomarin Pharm Inc Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
JP7253220B2 (ja) * 2015-07-31 2023-04-06 株式会社 イギス Ｃｎｐ環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
HUE057083T2 (hu) * 2015-12-08 2022-04-28 Biomarin Pharm Inc C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére
CA3007976C (en) * 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
ES3064816T3 (en) 2016-01-08 2026-04-29 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
EP3400021A1 (en) * 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
IL259827B2 (en) * 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
WO2017118700A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
DK3400019T3 (da) * 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
MX2018013546A (es) * 2016-05-06 2019-04-22 Phasebio Pharmaceuticals Inc Proteinas de fusion de elp para liberacion controlada y sostenida.
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
US11564974B2 (en) * 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
EP3574913A4 (en) 2017-01-24 2020-07-22 Daiichi Sankyo Company, Limited SMALL SIZE THERAPEUTIC AGENT
CA3056433A1 (en) * 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
EP3553079A1 (en) * 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
JP2023530273A (ja) * 2020-06-12 2023-07-14 ファーマイン コーポレイション Ｃ型ナトリウム利尿ペプチド及び癌の処置におけるその方法
CN115803338A (zh) * 2020-06-12 2023-03-14 药明公司 C型利尿钠肽及其治疗急性肺损伤的方法
CN111848776B (zh) * 2020-08-31 2022-03-18 江苏璟泽生物医药有限公司 聚乙二醇修饰的rhBNP及其制备方法
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
MX2024000526A (es) 2021-07-09 2024-02-02 Biomarin Pharm Inc Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os.
EP4444341A1 (en) * 2021-12-07 2024-10-16 BioMarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2023110758A1 (en) * 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用
EP4529454A1 (en) 2022-05-23 2025-04-02 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
TW202547558A (zh) * 2024-04-30 2025-12-16 大陸商北京炫景瑞醫藥科技有限公司 腎標靶遞送配體、共軛物、組合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2073751T3 (es) * 1990-04-20 1995-08-16 Hisayuki Matsuo Nuevo peptido con actividad fisiologica de origen porcino.
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
WO1994020534A1 (en) * 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5665704A (en) * 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5917019A (en) * 1997-02-13 1999-06-29 The Rockefeller University Altered telomere repeat binding factor 2
US6136040A (en) 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
IL125958A0 (en) 1998-08-27 1999-04-11 Yeda Res & Dev Animal model for fibroblast growth factor receptor associated chondrodysplasia
WO2000061631A1 (en) 1999-04-12 2000-10-19 Astrazeneca Ab Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
US8455438B2 (en) * 2008-12-29 2013-06-04 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
WO2012088608A1 (en) * 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof

Also Published As

Publication number Publication date
WO2009067639A3 (en) 2009-07-09
TWI367213B (en) 2012-07-01
AR069409A1 (es) 2010-01-20
US8377884B2 (en) 2013-02-19
TW200927758A (en) 2009-07-01
EP2217620A2 (en) 2010-08-18
US20100331256A1 (en) 2010-12-30
CA2705603A1 (en) 2009-05-28
WO2009067639A4 (en) 2009-09-11
WO2009067639A2 (en) 2009-05-28
CL2008003476A1 (es) 2009-08-14
JP2011504506A (ja) 2011-02-10
AU2008326327A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
PE20091067A1 (es) Variantes de peptidos natriureticos de tipo c
AR110887A2 (es) Región constante de anticuerpo mutante
JP2011511753A5 (es)
ES2571879T3 (es) Moléculas de una sola cadena de TNFSF
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
RU2011106744A (ru) Инсулин, стабилизированный галогеном
PE20130615A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
PE20121721A1 (es) Analogo peptidico de oxintomodulina
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
PE20120792A1 (es) Variantes de peptidos natriureticos de tipo c
RU2015143472A (ru) Конъюгаты инсулин-инкретин
AR070276A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion.
JP2013518115A5 (es)
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
RU2011134596A (ru) Аналоги оксинтомодулина
RU2013112616A (ru) Пептид cdca1 и включающее его фармацевтическое средство
ATE517119T1 (de) Einzelketteninsulin
HN2009001593A (es) Coagnistas de receptor de glucagon/glp-1
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
EA201100038A1 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
CO6241137A2 (es) Antagonistas ciclicos de peptido cxcr4

Legal Events

Date Code Title Description
FC Refusal